Valuation of new drug applications of pharmaceutical companies using compound option models

被引：0

作者：

Cassimon, D ^{[1
]}

Engelen, PJ ^{[1
]}

Thomassen, L ^{[1
]}

Wouwe, M ^{[1
]}

机构：

[1] Univ Antwerp, B-2020 Antwerp, Belgium

来源：

VALUE IN HEALTH | 2002年 / 5卷 / 06期

关键词：

D O I：

10.1016/S1098-3015(10)61403-9

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：530 / 530

页数：1

共 50 条

[1] A compound option valuation model of R&D-intensive pharmaceutical companies
Cassimon, D
Engelen, PJ
[J]. Korus 2004, Vol 3, Proceedings, 2004, : 209 - 212
[2] Option pricing: Valuation models and applications
Broadie, M
Detemple, JB
[J]. MANAGEMENT SCIENCE, 2004, 50 (09) : 1145 - 1177
[3] The valuation of a NDA using a 6-fold compound option
Cassimon, D
Engelen, PJ
Thomassen, L
Van Wouwe, M
[J]. RESEARCH POLICY, 2004, 33 (01) : 41 - 51
[4] Estimating and using GARCH models with VIX data for option valuation
Kanniainen, Juho
Lin, Binghuan
Yang, Hanxue
[J]. JOURNAL OF BANKING & FINANCE, 2014, 43 : 200 - 211
[5] Valuation of R&D compound option using Markov chain approach
Guglielmo D’Amico
Giovanni Villani
[J]. Annals of Finance, 2021, 17 : 379 - 404
[6] Valuation of R&D compound option using Markov chain approach
D'Amico, Guglielmo
Villani, Giovanni
[J]. ANNALS OF FINANCE, 2021, 17 (03) : 379 - 404
[7] The valuation of convertible bonds by using option pricing models: A Chinese case
Xia, XP
Zhan, WH
[J]. '99 INTERNATIONAL CONFERENCE ON MANAGEMENT SCIENCE & ENGINEERING, PROCEEDINGS, VOLS 1 AND 2, 1999, : 963 - 967
[8] Analysis of regulatory review times of new drugs in Japan: association with characteristics of new drug applications, regulatory agency, and pharmaceutical companies
Ishibashi, T.
Kusama, M.
Sugiyama, Y.
Ono, S.
[J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2012, 37 (06) : 657 - 663
[9] The Japan PDMA will require pharmaceutical companies to include risk management plans in all applications, for new drug or biosimilar products,
[J]. Reactions Weekly, 2012, 1431 (1) : 3 - 3
[10] How to deal with the requirements of the electronic submission of drug applications by pharmaceutical companies - Illustrated by variations
Schmitt, A
[J]. PHARMAZEUTISCHE INDUSTRIE, 2003, 65 (5A): : 525 - 530

← 1 2 3 4 5 →